Jennet Hojanazarova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennet Hojanazarova has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Shadmehr Demehri
Center for Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
2 shared publications - Erik B. Schiferle
Center for Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
1 shared publication - Kathryn E. Trerice
Center for Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
1 shared publication - Kenneth Ngo
Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, USA
1 shared publication - Marjan Azin
Center for Cancer Immunology, Krantz Family Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, USA
1 shared publication - Marjan Azin
Center for Cancer Immunology and Cutaneous Biology Research Center, Krantz Family Center for Cancer Research and Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA
1 shared publication
Latest Publications
- Open Access
- 11 August 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (6) , 100221
Topical Calcipotriol Plus Imiquimod Immunotherapy for Nonkeratinocyte Skin Cancers
- 11 August 2023
- Published by Elsevier in JID Innovations
- Vol. 3 (6) , 100221
Open AccessTopical Calcipotriol Plus Imiquimod Immunotherapy for Nonkeratinocyte Skin Cancers
- Open Access
Thymic Stromal Lymphopoietin Induction Suppresses Lung Cancer Development
Lung cancer is the leading cause of cancer deaths in the United States and across the world. Immunotherapies, which activate tumor-infiltrating cytotoxic T lymphocytes, have demonstrated efficacy for the treatment of advanced-stage lung cancer. However, the potential for harnessing the immune system against the early stages of lung carcinogenesis to prevent cancer development and recurrence remains unexplored. Using a mouse model of lung adenocarcinoma, we investigated the effects of thymic stromal lymphopoietin (TSLP) induction on early cancer development in the lungs. Herein, we demonstrate that systemic TSLP induction suppressed spontaneous lung cancer development in KrasG12D mice. TSLP drove a significant CD4+ T cell response to block lung cancer progression from atypical alveolar hyperplasia to adenocarcinoma. Our findings suggest that TSLP can be used in the early stages of lung cancer development to trigger a lasting immunity in the tissue and prevent the development of advanced disease.
Open AccessThymic Stromal Lymphopoietin Induction Suppresses Lung Cancer Development
Lung cancer is the leading cause of cancer deaths in the United States and across the world. Immunotherapies, which activate tumor-infiltrating cytotoxic T lymphocytes, have demonstrated efficacy for the treatment of advanced-stage lung cancer. However, the potential for harnessing the immune system against the early stages of lung carcinogenesis to prevent cancer development and recurrence remains unexplored. Using a mouse model of lung adenocarcinoma, we investigated the effects of thymic stromal lymphopoietin (TSLP) induction on early cancer development in the lungs. Herein, we demonstrate that systemic TSLP induction suppressed spontaneous lung cancer development in KrasG12D mice. TSLP drove a significant CD4+ T cell response to block lung cancer progression from atypical alveolar hyperplasia to adenocarcinoma. Our findings suggest that TSLP can be used in the early stages of lung cancer development to trigger a lasting immunity in the tissue and prevent the development of advanced disease.